{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21","value":"488.2"},{"groupId":"OG001","spread":"35","value":"1387"},{"comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 3310 and 3880 ng\\*hr/mL, respectively.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"55","value":"3990"},{"groupId":"OG004","spread":"28","value":"5110"},{"groupId":"OG005","spread":"73","value":"7474"},{"groupId":"OG006","spread":"43","value":"11410"},{"groupId":"OG007","spread":"9","value":"982.4"},{"groupId":"OG008","spread":"20","value":"2996"},{"groupId":"OG009","spread":"47","value":"2925"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"}],"units":"Participants"}],"description":"Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG000","title":"10 mg QD (Phase 1)"},{"description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.","id":"OG001","title":"25 mg QD (Phase 1)"},{"description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG002","title":"50 mg QD (Phase 1)"},{"description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG003","title":"75 mg QD (Phase 1)"},{"description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG004","title":"100 mg QD (Phase 1)"},{"description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.","id":"OG005","title":"150 mg QD (Phase 1)"},{"description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG006","title":"200 mg QD (Phase 1)"},{"description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG007","title":"35 mg BID (Phase 1)"},{"description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG008","title":"75 mg BID (Phase 1)"},{"description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG009","title":"100 mg BID (Phase 1)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours post-dose on Day -7 for all other groups.","title":"Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1)","type":"SECONDARY","unitOfMeasure":"Nanogram*hour/milliliter (ng*hr/mL)"}